PL2776032T3 - Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych - Google Patents
Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznychInfo
- Publication number
- PL2776032T3 PL2776032T3 PL12787343T PL12787343T PL2776032T3 PL 2776032 T3 PL2776032 T3 PL 2776032T3 PL 12787343 T PL12787343 T PL 12787343T PL 12787343 T PL12787343 T PL 12787343T PL 2776032 T3 PL2776032 T3 PL 2776032T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- hematologic malignancies
- cxcr4 antibody
- cxcr4
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| EP12787343.8A EP2776032B1 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2776032T3 true PL2776032T3 (pl) | 2019-03-29 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12787343T PL2776032T3 (pl) | 2011-11-09 | 2012-11-09 | Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (pl) |
| EP (1) | EP2776032B1 (pl) |
| JP (1) | JP6541350B2 (pl) |
| KR (1) | KR102024957B1 (pl) |
| CN (1) | CN104039320B (pl) |
| AU (1) | AU2012335553B2 (pl) |
| BR (1) | BR112014011144A2 (pl) |
| CA (1) | CA2855155A1 (pl) |
| CY (1) | CY1121331T1 (pl) |
| DK (1) | DK2776032T3 (pl) |
| EA (1) | EA026153B1 (pl) |
| ES (1) | ES2705001T3 (pl) |
| HR (1) | HRP20182183T1 (pl) |
| HU (1) | HUE043001T2 (pl) |
| IL (1) | IL232517B (pl) |
| LT (1) | LT2776032T (pl) |
| MX (1) | MX357100B (pl) |
| PL (1) | PL2776032T3 (pl) |
| PT (1) | PT2776032T (pl) |
| RS (1) | RS58102B1 (pl) |
| SG (1) | SG11201401386XA (pl) |
| SI (1) | SI2776032T1 (pl) |
| SM (1) | SMT201900026T1 (pl) |
| WO (1) | WO2013071068A2 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2066351T1 (sl) * | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| EP3066129B1 (en) * | 2013-11-06 | 2019-06-19 | Bristol-Myers Squibb Company | Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody |
| CA2930326C (en) | 2013-12-06 | 2022-09-06 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3572425A1 (en) * | 2013-12-17 | 2019-11-27 | AIMM Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
| CN106573976B (zh) * | 2014-02-06 | 2020-05-05 | 耶达研究及发展有限公司 | 抗cd84抗体、包含所述抗体的组合物及其用途 |
| JP2017508005A (ja) * | 2014-02-19 | 2017-03-23 | マイクロコンスタンツ チャイナ インク | ケモカイン受容体アンタゴニストおよびその併用療法 |
| DK3242685T3 (da) * | 2015-01-09 | 2022-07-25 | Adalta Ltd | Cxcr4-bindende molekyler |
| HRP20201334T1 (hr) | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| US11219694B2 (en) | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| WO2017083440A1 (en) * | 2015-11-09 | 2017-05-18 | The General Hospital Corporation D.B.A Massachusetts General Hospital | Unit dose formulations for use as an anti-fugetactic agent |
| CA3014530A1 (en) * | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| JP2019518006A (ja) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ |
| HRP20220237T1 (hr) | 2016-05-20 | 2022-04-29 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| WO2017216368A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CA3052070A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
| WO2018156609A1 (en) * | 2017-02-21 | 2018-08-30 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20210162009A1 (en) * | 2017-12-08 | 2021-06-03 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| CN112513079A (zh) * | 2018-03-13 | 2021-03-16 | 拉巴斯大学医院生物医学研究基金会 | 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| KR102825164B1 (ko) | 2018-03-27 | 2025-06-26 | 브리스톨-마이어스 스큅 컴퍼니 | 자외선 신호를 사용한 단백질 농도의 실시간 모니터링 |
| EP3774911A1 (en) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| KR20220012292A (ko) | 2019-05-23 | 2022-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 배양 배지를 모니터링하는 방법 |
| CN114746095B (zh) | 2019-10-08 | 2025-01-24 | 达纳-法伯癌症研究所有限公司 | Hck作为myd88突变疾病的治疗靶点 |
| US12679842B2 (en) | 2019-10-08 | 2026-07-14 | Dana-Farber Cancer Institute, Inc. | HCK as a therapeutic target in MYD88 mutated diseases |
| JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
| PT4267105T (pt) | 2020-12-28 | 2025-04-30 | Bristol Myers Squibb Co | Composições de anticorpos e métodos de utilização das mesmas |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| KR20240156411A (ko) | 2022-03-09 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 단백질의 일시적 발현 |
| US20240294651A1 (en) * | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| CN119119196B (zh) * | 2024-08-01 | 2025-09-09 | 青岛大学 | 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| ES2374526T3 (es) | 2003-09-04 | 2012-02-17 | Medarex, Inc. | Vector de expresión. |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| HUE028055T2 (en) | 2006-02-28 | 2016-11-28 | Pharma Mar Sa | Improved treatment of myeloma multiplex |
| SI2066351T1 (sl) * | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EP2297206A1 (en) | 2008-05-14 | 2011-03-23 | Eli Lilly And Company | Anti-cxcr4 antibodies |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| JP5709766B2 (ja) * | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用 |
| RU2636614C2 (ru) * | 2009-05-19 | 2017-11-24 | Вивия Байотек С.Л. | Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования |
| EP2605797A2 (en) | 2010-08-20 | 2013-06-26 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
-
2012
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/hu unknown
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/lt unknown
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en not_active Ceased
- 2012-11-09 PL PL12787343T patent/PL2776032T3/pl unknown
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/pt not_active Application Discontinuation
- 2012-11-09 HR HRP20182183TT patent/HRP20182183T1/hr unknown
- 2012-11-09 ES ES12787343T patent/ES2705001T3/es active Active
- 2012-11-09 MX MX2014005267A patent/MX357100B/es active IP Right Grant
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
- 2012-11-09 SI SI201231459T patent/SI2776032T1/sl unknown
- 2012-11-09 PT PT12787343T patent/PT2776032T/pt unknown
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/zh not_active Expired - Fee Related
- 2012-11-09 SM SM20190026T patent/SMT201900026T1/it unknown
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/ko not_active Expired - Fee Related
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 EA EA201490957A patent/EA026153B1/ru not_active IP Right Cessation
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/ja not_active Expired - Fee Related
- 2012-11-09 RS RS20181552A patent/RS58102B1/sr unknown
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/el unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401386XA (en) | Treatment of hematologic malignancies with an anti-cxcr4 antibody | |
| IL228738A0 (en) | Antibodies for cancer treatment | |
| ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
| IL232055B (en) | Anti-1htra antibodies and methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| PT2768857T (pt) | Métodos para purificar anticorpos | |
| EP2734234A4 (en) | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF | |
| IL232510A0 (en) | Treatment methods using an antibody against gamma interferon | |
| EP2736330A4 (en) | COMPOUNDS AND METHODS | |
| HUE048876T2 (hu) | Rákos megbetegedések kezelése | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| EP2747560A4 (en) | CONNECTIONS AND METHODS | |
| IL233317A0 (en) | Anti-lrp5 antibodies and methods of use | |
| EP2736332A4 (en) | CONNECTIONS AND METHODS | |
| EP2736329A4 (en) | COMPOUNDS AND METHODS | |
| EP2709999A4 (en) | CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION | |
| EP2798087A4 (en) | CELL ANALYSIS OF ORGANIC LIQUIDS | |
| IL226246A0 (en) | Methods of treating cancer | |
| IL228430A0 (en) | Cancer treatment | |
| ZA201403739B (en) | Methods of treatment with deferiprone | |
| EP2785742A4 (en) | ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF | |
| IL228706A0 (en) | Divided conduit and process for forming | |
| GB201121564D0 (en) | Use of antibody | |
| IL232266A0 (en) | Cancer treatment methods | |
| IL229109A0 (en) | Cancer diagnosis |